DXCM 8-K Current Reports
DEXCOM INC - 277 current reports
DEXCOM INC 8-K Report, Financial Results (Jul 30, 2026)
DexCom, Inc. (DXCM) has filed an 8-K report on July 30, 2026, to disclose its financial results for the second quarter ended June 30, 2026. The primary purpose of this filing is to furnish a press release announcing these results, which provides investors with key performance indicators and financial condition updates. While this information is furnished and not deemed 'filed' for liability purposes under Section 18 of the Exchange Act, it represents the company's official communication regarding its recent performance. Investors should refer to the press release (Exhibit 99.1) for specific details on revenue, profitability, and any forward-looking statements or guidance provided by DexCom for the upcoming periods. The filing indicates that further details beyond the summary provided in the 8-K's Item 2.02 will be found within this attached press release, which is crucial for a comprehensive understanding of the company's current financial standing and future outlook.
DEXCOM INC 8-K Report, Shareholder Vote Results (May 28, 2026)
DexCom, Inc. (DXCM) held its 2026 Annual Meeting of Stockholders on May 27, 2026, where key corporate governance and operational matters were presented to shareholders for a vote. The meeting saw strong participation, with a quorum established by the presence of 336,525,352 shares, representing over 87% of the outstanding common stock as of the April 1, 2026 record date. The primary outcomes of the meeting include the re-election of all twelve nominated directors to the board, each for a term extending to the 2027 annual meeting. Furthermore, stockholders overwhelmingly ratified the appointment of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The compensation of the company's named executive officers was also approved on an advisory, non-binding basis.
DEXCOM INC 8-K Report, Regulation FD Disclosure (May 15, 2026)
DEXCOM INC. (DXCM) filed an 8-K on May 15, 2026, detailing key strategic and financial announcements made during their 2026 Investor Day. The company presented ambitious long-range financial targets through 2030, emphasizing sustained organic revenue growth and significant improvements in profitability margins. These targets signal strong confidence in Dexcom's market position and future performance, which will be closely watched by investors. In addition to outlining its growth trajectory, Dexcom's Board of Directors approved a substantial $1.0 billion share repurchase program, signaling a commitment to returning capital to shareholders and potentially enhancing shareholder value. This strategic move, coupled with the long-term financial outlook, provides investors with a comprehensive view of Dexcom's forward-looking strategy, focusing on both growth initiatives and capital allocation.
DEXCOM INC 8-K Report, Financial Results (Apr 30, 2026)
DexCom, Inc. (DXCM) has filed an 8-K report on April 30, 2026, to announce its financial results for the first quarter ended March 31, 2026. While the filing itself is brief, it references a press release (Exhibit 99.1) containing the detailed financial and operational performance for the period. Investors should refer to this press release for crucial information regarding revenue, profitability, and any forward-looking guidance provided by the company. This filing serves as a notification mechanism for material updates. The company's performance in Q1 2026, as detailed in the press release, will be a key indicator for assessing its current trajectory and future prospects. Investors are advised to examine the press release for specific metrics and commentary that could influence their investment decisions, paying close attention to any management commentary on market trends, product adoption, and competitive landscape.
DEXCOM INC 8-K Report, Executive Changes (Mar 2, 2026)
This 8-K filing from DexCom, Inc. (DXCM) on March 2, 2026, primarily reports on the return of Kevin R. Sayer to his role as Executive Chairman of the Board, effective March 2, 2026, after a temporary leave of absence. Mr. Sayer's transition from CEO to Executive Chairman was previously announced, and his return signifies a continuation of his leadership and strategic guidance for the company. This filing also details the new compensation arrangement for his role as Executive Chairman.
DEXCOM INC 8-K Report, Executive Changes (Feb 26, 2026)
DexCom, Inc. (DXCM) announced a strategic expansion of its Board of Directors, increasing its size to twelve members with the immediate appointment of Albert F. (“Rick”) Osterloh, IV. Mr. Osterloh's appointment is effective as of February 26, 2026, and he will serve until the 2026 annual meeting of stockholders. His addition is expected to bring valuable experience to the company, as he has been appointed to key committees, including the Compensation Committee and the Technology Committee, underscoring his role in governance and strategic oversight. This move appears to be a proactive step in strengthening DexCom's leadership structure. Mr. Osterloh's independence has been confirmed, and his compensation aligns with the company's non-employee director program, including an initial equity grant of $500,000 in restricted stock units vesting over three years, and a pro-rated annual equity grant for his service. Investors should monitor how Mr. Osterloh's expertise influences the company's strategic decisions, particularly in technology and compensation, moving forward.
DEXCOM INC 8-K Report, Financial Results (Feb 12, 2026)
DexCom, Inc. (DXCM) has filed an 8-K report on February 12, 2026, to announce its financial results for the fourth quarter and full year ended December 31, 2025. The primary purpose of this filing is to furnish the accompanying press release, which contains key financial and operational updates for investors. Investors should refer to the press release (Exhibit 99.1) for the detailed financial performance, strategic initiatives, and forward-looking statements made by the company. While the specific financial figures are not detailed within the 8-K text itself, this report signals the company's official communication of its year-end and quarterly performance. The furnishing of this information means it is provided for informational purposes and is not deemed "filed" under the Securities Exchange Act of 1934, thus not subject to specific liability sections of that act. Investors are advised to carefully review the press release for comprehensive details on revenue, profitability, product development, and any guidance for the upcoming fiscal year.
DEXCOM INC 8-K Report, Financial Results (Jan 12, 2026)
This 8-K filing from DexCom, Inc. (DXCM) serves as a notification regarding upcoming presentations and releases of preliminary financial results. President and CEO Jake Leach is scheduled to present at the J.P. Morgan 44th Annual Healthcare Conference on January 12, 2026, where he will share unaudited financial results for the fourth quarter and full fiscal year 2025, along with initial financial outlook for fiscal year 2026. Investors should note that these results are preliminary and subject to finalization in the upcoming Form 10-K. The filing also references a business update press release issued on January 7, 2026, and includes these materials as exhibits. It's crucial for investors to understand that forward-looking statements within these releases are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially.
DEXCOM INC 8-K Report, Executive Changes (Dec 22, 2025)
DexCom, Inc. (DXCM) has filed an 8-K report detailing the official appointment of Jacob S. Leach as President and Chief Executive Officer, effective January 1, 2026. This transition follows Mr. Leach's service as interim principal executive officer during Kevin R. Sayer's medical leave. The filing outlines the key terms of Mr. Leach's new role, including an annual base salary of $1,150,000 and a target bonus opportunity of 150% of his base salary. Furthermore, Mr. Leach will receive significant equity awards, comprising restricted stock units valued at $7,500,000 and performance stock units with a target value of $7,500,000, both vesting over several years and contingent on continued service and performance conditions. This leadership change represents a pivotal moment for DexCom as it moves forward under new permanent executive leadership. Investors will be keen to observe Mr. Leach's strategic direction and execution in his permanent CEO role, especially considering the substantial incentive package designed to align his interests with long-term shareholder value. The report also confirms that Kevin R. Sayer is expected to return from his medical leave around March 2026, with Mark Foletta continuing as interim Chairman of the Board until then.
DEXCOM INC 8-K Report, Financial Results (Oct 30, 2025)
DexCom, Inc. (DXCM) has filed an 8-K report on October 30, 2025, to announce its financial results for the quarter ended September 30, 2025. This filing primarily serves to furnish a press release detailing these results and other pertinent information. Investors should note that the information provided in this Item 2.02 and its exhibit is furnished and not deemed "filed" for regulatory purposes, meaning it does not carry the same liabilities as a formally filed document under Section 18 of the Exchange Act. The press release, furnished as Exhibit 99.1, contains DexCom's operational and financial performance for the third quarter of 2025. While the specifics of the financial results are within the attached press release, this 8-K filing itself is the mechanism through which the market is being officially informed of these key performance indicators. Investors are encouraged to review Exhibit 99.1 for detailed financial metrics and commentary.
DEXCOM INC 8-K Report, Executive Changes (Oct 27, 2025)
DexCom, Inc. (DXCM) announced a change in its Board of Directors composition through an 8-K filing on October 27, 2025. The company has appointed Dr. Euan Ashley as a new director, effective immediately, increasing the Board's size to ten members. Dr. Ashley's appointment is significant as he brings expertise and will serve on the Nominating and Governance Committee and the Technology Committee. This move is part of a broader board expansion strategy previously announced, which includes the appointment of Jacob S. Leach effective January 1, 2026. The appointment of Dr. Ashley is structured with a standard director compensation package, including an initial equity grant of $500,000 in restricted stock units (RSUs) vesting over three years, and eligibility for future annual equity awards. His qualifications are deemed independent, aligning with Nasdaq listing standards. This strategic addition to the board aims to bolster governance and technological oversight, reflecting DexCom's commitment to strong leadership as it continues to grow.
DEXCOM INC 8-K Report, Executive Changes (Sep 16, 2025)
DexCom, Inc. (DXCM) has announced that its Chief Executive Officer and Chairman of the Board, Kevin R. Sayer, is taking a temporary medical leave of absence, effective September 14, 2025. This development necessitates a temporary leadership transition to ensure continuity of operations and strategic direction. In response, the Board of Directors has appointed Jacob S. Leach, currently President and Chief Operating Officer, to serve as the interim principal executive officer. Additionally, Mark Foletta, the Lead Independent Director, has been appointed as the interim Chairman of the Board. Investors should note that neither Mr. Leach nor Mr. Foletta will receive additional compensation for these interim roles, signaling a commitment to stable governance during this period. The company has emphasized that Mr. Leach's appointment is not subject to any specific arrangements or understandings with other parties and that he has no material interests in any reportable transactions.
DEXCOM INC 8-K Report, Financial Results (Jul 30, 2025)
DexCom, Inc. (DXCM) has filed an 8-K report detailing its financial results for the quarter ended June 30, 2025, and announcing significant leadership transitions. While specific financial figures are not provided in this extract, the company has confirmed the release of its quarterly earnings through a press release furnished as Exhibit 99.1. Investors should refer to this press release for detailed performance metrics and operational highlights for the period. The most substantial news in this filing pertains to executive leadership. CEO Kevin R. Sayer will retire from his CEO role effective January 1, 2026, transitioning to Executive Chairman. Concurrently, current President and COO, Jacob S. Leach, will assume the CEO position on January 1, 2026. Mr. Leach will also join the Board of Directors as part of these changes. The company stated that no new compensatory arrangements have been finalized for these roles as of the filing date.
DEXCOM INC 8-K Report, Executive Changes (May 13, 2025)
DexCom, Inc. (DXCM) has announced a significant leadership change with the promotion of Jacob S. Leach to President and Chief Operating Officer, effective immediately. This appointment places Mr. Leach directly under CEO Kevin Sayer and signifies a strengthening of the operational leadership team. Investors should note that Mr. Leach's compensation has been adjusted to reflect his new role, including a base salary of $800,000 and eligibility for a performance-based annual cash bonus targeted at 100% of his base salary. This promotion is a key development for DexCom as it continues to execute its growth strategy in the diabetes technology market. The elevated role for Mr. Leach, who has been with the company, suggests confidence in his ability to drive operational execution and strategic initiatives. The associated compensation structure is designed to incentivize strong performance and align executive interests with those of shareholders.
DEXCOM INC 8-K/A Report, Executive Changes (May 9, 2025)
DexCom, Inc. (DXCM) has filed an amendment to its prior 8-K filing, specifically addressing the committee appointments for newly appointed board member Ms. Renée Galá. Initially appointed to the board on March 6, 2025, the company is now confirming her service on two key committees: the Audit Committee and the Compensation Committee. These appointments are effective immediately as of May 9, 2025.
DEXCOM INC 8-K Report, Executive Changes (May 9, 2025)
DexCom, Inc. (DXCM) filed an 8-K on May 9, 2025, detailing the outcomes of its Annual Meeting of Stockholders held on May 8, 2025. The primary focus for investors is the stockholder approval of significant amendments to the company's equity and employee stock purchase plans. Specifically, the Amended and Restated 2015 Equity Incentive Plan (A&R 2015 EIP) was approved, increasing the share reserve by 3.4 million shares, and the Amended and Restated 2015 Employee Stock Purchase Plan (A&R 2015 ESPP) was also approved, adding 8 million shares to its reserve. These approvals are crucial for DexCom's ability to continue attracting and retaining talent through stock-based compensation and employee ownership programs, supporting future growth and operational expansion. In addition to compensation-related plans, stockholders also elected nine directors to the board, ratified Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year 2025, and provided advisory approval for named executive officer compensation. A notable governance change was the board's decision to decrease its size to nine directors, effective May 8, 2025. The substantial 'Votes For' on all proposals indicate strong shareholder support for management's proposed actions and compensation strategies.
DEXCOM INC 8-K Report, Executive Changes (May 2, 2025)
DexCom, Inc. (DXCM) announced in an 8-K filing dated May 2, 2025, that director Karen Dahut will be resigning from the Board of Directors and all associated committees, effective May 8, 2025. The company has explicitly stated that Ms. Dahut's departure is not due to any disagreements with the company, its management, or its board, nor is it related to any issues concerning the company's operations, policies, or practices. This communication signals a routine board transition rather than a cause for concern regarding internal discord or operational challenges.
DEXCOM INC 8-K Report, Financial Results (May 1, 2025)
DexCom, Inc. (DXCM) announced its first quarter 2025 financial results and a significant new share repurchase program in an 8-K filing dated May 1, 2025. While the press release containing the detailed financial results is furnished as an exhibit and not deemed 'filed' for liability purposes, the announcement of these results is a key event for investors. The company also revealed a new authorization for a share repurchase program valued at up to $750.0 million of its outstanding common stock, with a repurchase period extending through June 30, 2026. This dual announcement provides investors with an update on DexCom's recent performance and a clear signal of management's confidence in the company's value, demonstrated by the substantial capital allocation towards share buybacks. The flexibility in repurchase methods, including Rule 10b5-1 trading plans, allows DexCom to execute the program efficiently while navigating market conditions. Investors will be keen to examine the specific financial metrics released in the accompanying press release to understand the drivers behind these results and the ongoing strategic direction of the company.
DEXCOM INC 8-K Report, Auditor Change (Mar 25, 2025)
DexCom, Inc. (DXCM) has announced a change in its independent registered public accounting firm. The Audit Committee of the Board of Directors, on March 21, 2025, dismissed Ernst & Young LLP (EY) as the Company's auditor. This change is effective for the fiscal years ended December 31, 2024 and 2023, and the subsequent interim period. The company states that there were no disagreements or reportable events with EY during these periods, and EY has confirmed its agreement with this statement. This transition is a routine procedural event, but investors should be aware of the change in auditor. Concurrently, DexCom has engaged Deloitte & Touche LLP (Deloitte) as its new independent registered public accounting firm for the fiscal year ending December 31, 2025. The company has confirmed that there were no consultations with Deloitte on accounting principles, disagreements, or reportable events prior to this engagement. The engagement of a new auditor is a common occurrence and typically does not indicate any underlying issues with the company's financial reporting, but it does mark a significant change in the oversight of DexCom's financial statements.
DEXCOM INC 8-K Report, Executive Changes (Mar 10, 2025)
DexCom, Inc. (DXCM) announced a key governance update on March 10, 2025, via an 8-K filing. The company has expanded its Board of Directors to eleven members with the immediate appointment of Renée Galá. Ms. Galá's appointment is effective through the 2025 annual meeting of stockholders and she has been deemed an independent director, aligning with Nasdaq listing standards. This expansion and appointment suggest a proactive approach by DexCom to strengthen its board's expertise and oversight. Investors should note that Ms. Galá's compensation includes an initial equity grant of $500,000 in Restricted Stock Units (RSUs) vesting over three years, and a pro-rated annual equity grant of approximately $56,986. This compensation structure is typical for non-employee directors and aligns their interests with long-term shareholder value through equity ownership.
DEXCOM INC 8-K Report, Regulation FD Disclosure (Mar 7, 2025)
DexCom, Inc. (DXCM) disclosed on March 7, 2025, that it received a warning letter from the U.S. Food and Drug Administration (FDA) on March 4, 2025, following inspections of its San Diego and Mesa facilities. The FDA cited deficiencies related to manufacturing processes and quality management systems, stemming from earlier Form 483 observations. Importantly, the company stated that this warning letter does not restrict its ability to produce, market, manufacture, or distribute products, nor does it necessitate a recall or prevent the pursuit of 510(k) clearance for new products. Despite the seriousness of the FDA's concerns, DexCom asserted that it does not expect a material impact on its manufacturing capacity or its previously issued fiscal year 2025 revenue guidance. The company is actively preparing a response to the warning letter and has already submitted responses to the Form 483. While DexCom is committed to corrective actions and updates to the FDA, it cannot guarantee the FDA's satisfaction with its response or provide an estimated timeline for resolution, acknowledging that further regulatory action remains a possibility.
DEXCOM INC 8-K Report, Financial Results (Feb 13, 2025)
DexCom, Inc. (DXCM) filed an 8-K on February 13, 2025, primarily to announce its financial results for the fourth quarter and full year ended December 31, 2024. The press release containing these results, furnished as Exhibit 99.1, is the main focus of this filing. Investors should refer to this press release for detailed financial performance, operational updates, and any forward-looking statements regarding the company's outlook. This filing serves as the official notification of these key financial outcomes. While the 8-K itself is brief, the accompanying press release is crucial for understanding DexCom's performance in the period. Investors will be looking for information on revenue growth, profitability metrics, any significant changes in guidance, and commentary on market trends impacting the continuous glucose monitoring (CGM) sector. The furnished information is not considered "filed" for liability purposes under Section 18 of the Exchange Act, but it is the primary source for the reported financial and operational data.
DEXCOM INC 8-K Report, Financial Results (Jan 13, 2025)
DexCom, Inc. (DXCM) has filed a Form 8-K to provide preliminary, unaudited financial results for the fourth quarter and full fiscal year 2024, along with initial financial guidance for fiscal year 2025. These updates were shared during a presentation at the J.P. Morgan 43rd Annual Healthcare Conference on January 13, 2025, by CEO Kevin Sayer. Investors should note that these results are preliminary and subject to finalization during the preparation of the upcoming Form 10-K. The filing also contains forward-looking statements regarding revenue, gross profit margin, and operating margin, which are subject to inherent risks and uncertainties that could cause actual results to differ materially.
DEXCOM INC 8-K Report, Material Agreement (Dec 23, 2024)
DexCom, Inc. (DXCM) has announced the resolution of its ongoing global patent litigation with Abbott Diabetes Care, Inc. (Abbott). The parties entered into a comprehensive settlement and patent cross-license agreement on December 20, 2024, which effectively terminates all outstanding legal disputes concerning patent infringements and invalidation claims. This agreement is highly positive for DexCom as it eliminates significant legal costs and uncertainty associated with the protracted litigation. The terms include a royalty-free, non-exclusive, and fully paid-up license for both companies to use certain patents related to analyte sensing, including those previously contested. Furthermore, a mutual covenant not to sue is established until December 20, 2034, providing a decade of peace from further patent challenges from Abbott. This resolution allows DexCom to focus its resources and strategic efforts entirely on its business operations and innovation without the overhang of this litigation.
DEXCOM INC 8-K Report, Financial Results (Oct 24, 2024)
DexCom, Inc. (DXCM) has filed an 8-K report on October 24, 2024, primarily to announce its financial results for the quarter ended September 30, 2024, via a press release furnished as Exhibit 99.1. While the specific financial figures are not detailed within the 8-K text itself, this filing serves as the official notification channel for investors and the market regarding the company's most recent performance. Investors should refer to the press release (Exhibit 99.1) for comprehensive details on revenue, profitability, and any forward-looking guidance provided by the company. This filing is crucial for understanding DexCom's operational and financial standing as of the third quarter of 2024. This report is furnished, not filed, meaning it does not carry the same legal liabilities as a fully filed document under Section 18 of the Exchange Act. However, it remains the primary source for timely information dissemination regarding DexCom's financial results. Investors and analysts will be closely examining the information within the accompanying press release to assess the company's growth trajectory, competitive position, and overall financial health within the diabetes technology market.
DEXCOM INC 8-K Report, Financial Results (Jul 25, 2024)
DexCom, Inc. (DXCM) has filed an 8-K report on July 25, 2024, announcing two significant developments for investors. Firstly, the company issued a press release detailing its financial results for the quarter ended June 30, 2024. While the specifics of these results are not included directly in the 8-K text, their release indicates a regular update on operational performance. Investors should refer to the furnished press release (Exhibit 99.1) for detailed financial metrics, revenue figures, and profitability. Secondly, DexCom's Board of Directors has authorized a substantial share repurchase program valued at up to $750.0 million, with repurchases expected to conclude by June 30, 2025. This program signals management's confidence in the company's intrinsic value and its commitment to returning capital to shareholders. The repurchases can be executed through various market mechanisms, including 10b5-1 plans, at the company's discretion, depending on market conditions.
DEXCOM INC 8-K Report, Shareholder Vote Results (May 24, 2024)
This 8-K filing from DexCom, Inc. (DXCM) reports the outcomes of its 2024 Annual Meeting of Stockholders held on May 22, 2024. The meeting resulted in the overwhelming election of all ten director nominees, underscoring strong board support from shareholders. Additionally, shareholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, a crucial vote of confidence in the company's financial oversight. Furthermore, the advisory vote to approve the compensation of named executive officers passed, indicating general shareholder satisfaction with executive pay structures. However, the filing also details the outcomes of two stockholder proposals, with one concerning pay equity disclosure failing to gain majority support, while a proposal for transparency in lobbying was approved. These results provide insight into shareholder sentiment on corporate governance and executive compensation.
DEXCOM INC 8-K Report, Financial Results (Apr 25, 2024)
DexCom, Inc. (DXCM) has filed an 8-K report on April 25, 2024, to announce its financial results for the first quarter ended March 31, 2024. The report primarily directs investors to a furnished press release (Exhibit 99.1) for detailed financial performance and operational updates. Investors should note that the information provided in this Item 2.02 and Exhibit 99.1 is furnished, not filed, meaning it is not subject to the same liability provisions as a formally filed document under Section 18 of the Exchange Act and is not automatically incorporated into other DexCom filings unless specifically referenced. This disclosure style is common for earnings releases, with the full details of the quarter's performance contained within the accompanying press release.
DEXCOM INC 8-K Report, Material Agreement (Feb 15, 2024)
DexCom, Inc. (DXCM) has entered into a Warrant Termination Agreement with Bank of America, N.A. (BofA) on February 13, 2024, to terminate outstanding warrants related to its 0.75% Convertible Senior Notes due 2023. These warrants were originally issued in connection with the convertible notes and associated hedge and warrant transactions with BofA and JPMorgan Chase Bank (JPM). The termination agreement will resolve approximately 10.3 million shares of common stock warrants held by BofA. In exchange for the warrant termination, DexCom will issue shares of its common stock to BofA. The number of shares will be determined by the daily volume-weighted average price of DexCom's common stock over a specified averaging period expected to conclude in the first quarter of 2024. This transaction is being conducted under an exemption from registration, implying it is not being offered to the public and is intended to simplify the company's capital structure and remove potential future dilution from these specific warrants.
DEXCOM INC 8-K Report, Financial Results (Feb 8, 2024)
DexCom, Inc. (DXCM) has filed an 8-K report on February 8, 2024, to announce its financial results for the fourth quarter and full year ended December 31, 2023. The filing primarily consists of a press release (Exhibit 99.1) detailing these results and other relevant information. Investors should note that the information furnished in this Item 2.02 is not considered "filed" for legal liability purposes under Section 18 of the Exchange Act, nor is it automatically incorporated into future SEC filings unless specifically referenced. While the 8-K itself does not contain the detailed financial figures, it directs investors to the accompanying press release for the complete financial performance. This includes key metrics for both the recent quarter and the full fiscal year, providing a comprehensive update on the company's operational and financial condition. Investors are encouraged to review Exhibit 99.1 for the specific revenue, profit, and any forward-looking guidance provided by DexCom.
DEXCOM INC 8-K Report, Financial Results (Jan 8, 2024)
DexCom, Inc. (DXCM) has filed an 8-K report on January 8, 2024, providing preliminary, unaudited financial results for the fourth quarter and full fiscal year 2023, along with an initial financial outlook for 2024. The company anticipates strong revenue growth, with Q4 2023 revenue expected to reach at least $1.030 billion, a 26% increase year-over-year. For the full fiscal year 2023, total revenue is projected to be around $3.62 billion, marking a 24% increase from 2022. Looking ahead to fiscal year 2024, DexCom has provided an initial revenue outlook, forecasting a total revenue range of approximately $4.15 billion to $4.35 billion. This guidance suggests continued growth for the company in the upcoming year, driven by its diabetes monitoring technologies. Investors should note that these results are preliminary and unaudited, subject to finalization in DexCom's upcoming Form 10-K filing.
DEXCOM INC 8-K Report, Corporate Update (Nov 2, 2023)
DexCom, Inc. (DXCM) announced on November 2, 2023, through an 8-K filing, its entry into an accelerated share repurchase (ASR) agreement with Bank of America, N.A. for up to $500.0 million. This strategic move signals management's confidence in the company's intrinsic value and its commitment to returning capital to shareholders. The company has already made an initial payment of $500.0 million and received approximately 4.7 million shares, effective October 31, 2023. This ASR transaction is part of DexCom's previously authorized $500.0 million share repurchase program and is expected to be finalized within the fourth quarter of 2023. The ultimate number of shares repurchased will be determined by the daily volume-weighted average price, less a discount, with potential for additional shares or a cash settlement. This action suggests the company believes its shares are currently undervalued, aiming to enhance shareholder value by reducing the outstanding share count.
DEXCOM INC 8-K Report, Financial Results (Oct 26, 2023)
DexCom, Inc. (DXCM) filed an 8-K on October 26, 2023, to announce its financial results for the third quarter ended September 30, 2023. The filing includes a press release detailing the company's performance and other relevant information. While this 8-K is primarily an informational filing and the contents are furnished rather than deemed 'filed' for regulatory purposes, it provides investors with timely updates on the company's operational and financial standing. Investors should refer to the furnished press release for specific details on the quarterly performance, as it contains the primary financial disclosures. This report is crucial for understanding DexCom's recent business trajectory and financial health as it relates to the third quarter of 2023. It serves as a direct communication channel from the company to its shareholders regarding its financial results and operational highlights. Investors seeking a comprehensive understanding of DexCom's performance should carefully review the accompanying press release, which is incorporated by reference into this filing.
DEXCOM INC 8-K Report, Corporate Update (Oct 26, 2023)
Dexcom, Inc. (DXCM) announced on October 24, 2023, that its Board of Directors has approved a significant share repurchase program valued at up to $500 million of its outstanding common stock. This program, set to conclude by October 31, 2024, signals management's confidence in the company's intrinsic value and its commitment to enhancing shareholder returns. The buyback will be executed opportunistically through various methods, including open market transactions and privately negotiated deals, adhering to regulatory guidelines.
DEXCOM INC 8-K Report, Executive Changes (Aug 28, 2023)
DexCom, Inc. (DXCM) announced the appointment of Rimma Driscoll to its Board of Directors, effective August 24, 2023. Ms. Driscoll will fill a vacant seat and will also serve on the Audit Committee and the Technology Committee. Her appointment strengthens the board's expertise and governance structure, particularly in areas critical to DexCom's business operations and innovation. She is considered an independent director under Nasdaq listing standards. In connection with her appointment, Ms. Driscoll will receive equity compensation, including an initial retainer grant of restricted stock units (RSUs) valued at $500,000, vesting over three years, and a customary annual RSU grant valued at $325,000, vesting in one year. This compensation aligns with the company's policy for non-employee directors and is intended to incentivize long-term value creation. The company also announced this appointment via a press release, which is furnished as an exhibit to this filing.
DEXCOM INC 8-K Report, Financial Results (Jul 27, 2023)
DexCom, Inc. (DXCM) filed an 8-K on July 27, 2023, primarily to announce its financial results for the second quarter ended June 30, 2023. While the 8-K itself doesn't contain the detailed financial figures, it references a furnished press release (Exhibit 99.1) that provides these operational and financial updates. Investors should refer to this press release for specific revenue, profit, and other key performance indicators for the quarter. The filing also includes standard legal disclaimers, noting that the information furnished is not considered "filed" for certain regulatory purposes, meaning it doesn't automatically incorporate into other SEC filings unless specifically referenced. This is a routine disclosure practice for companies announcing earnings via press release.
DEXCOM INC 8-K Report, Regulation FD Disclosure (Jun 26, 2023)
DexCom, Inc. (DXCM) filed an 8-K on June 26, 2023, primarily to disclose information presented at their Investor Day on June 23, 2023. The key takeaway for investors is an update to the company's long-range financial targets. While the specific updated targets are detailed in the furnished press release (Exhibit 99.1), this filing indicates a forward-looking strategic communication from DexCom regarding its growth trajectory and financial outlook. Investors should review the associated press release and Investor Day presentation, which are referenced in the filing and available on DexCom's investor relations website, for comprehensive details on these updated financial goals. This information is crucial for understanding management's expectations for future performance and assessing the company's long-term value proposition. It's important to note that the information furnished under Item 7.01 is not considered "filed" and therefore does not carry the same regulatory implications as formally filed information.
DEXCOM INC 8-K Report, Executive Changes (May 19, 2023)
This Form 8-K filing from DexCom, Inc. (DXCM) on May 19, 2023, details significant updates to executive compensation and outlines the results of its 2023 Annual Meeting of Stockholders. The company amended its Severance and Change in Control Plan, enhancing severance benefits for its Chief Executive Officer (CEO) and other senior executives. These changes, recommended by an independent compensation consultant, aim to align Dexcom's executive compensation with peer companies and include extended salary severance, COBRA premium coverage, and increased target bonus payouts upon termination without cause or for good reason, especially during a change of control period. The filing also reports on the outcomes of the Annual Meeting, where stockholders overwhelmingly re-elected all seven director nominees, ratified the appointment of Ernst & Young LLP as the independent auditor for fiscal year 2023, and approved an advisory vote on executive compensation. Notably, stockholders voted to hold the advisory "say on pay" vote annually. However, a stockholder proposal regarding pay equity disclosure was rejected by a significant margin. These actions provide insights into corporate governance and executive remuneration practices at Dexcom.
DEXCOM INC 8-K Report, Material Agreement (May 5, 2023)
DEXCOM INC (DXCM) filed an 8-K on May 5, 2023, detailing the completion of a $1.25 billion offering of 0.375% Convertible Senior Notes due 2028. The offering, which included the full exercise of an option to purchase additional notes, was conducted as a private placement under Section 4(a)(2) and Rule 144A, targeting qualified institutional buyers. The net proceeds, estimated at approximately $1,230.6 million after expenses and a $101.3 million allocation for capped call transactions, will be used for capital expenditures, working capital, and general corporate purposes. A significant portion of the proceeds, approximately $188.7 million, was also used to repurchase shares of the Company's common stock. The convertible notes mature on May 15, 2028, with an interest rate of 0.375% payable semi-annually. The notes are unsecured and unsubordinated obligations of DexCom. The company has the option to redeem the notes under specific conditions after May 20, 2026. The notes are convertible into cash, shares of common stock, or a combination thereof, at an initial conversion rate of 6.1571 shares per $1,000 principal amount, implying an initial conversion price of approximately $162.41 per share. Conversion is subject to certain conditions, including stock price performance thresholds and specific corporate events. To mitigate potential dilution from the conversion of these notes, DexCom entered into capped call transactions, which are expected to reduce dilution and/or offset cash payments, subject to a cap price of approximately $212.62.
DEXCOM INC 8-K Report, Corporate Update (May 3, 2023)
DexCom, Inc. (DXCM) announced on May 3, 2023, the successful pricing of its offering of $1.1 billion in aggregate principal amount of 0.375% Convertible Senior Notes due 2028. These notes were offered in a private placement to qualified institutional buyers under Rule 144A, indicating a strategic move to secure capital from sophisticated investors. The company also provided an option for the initial purchasers to buy an additional $150.0 million in notes, suggesting strong investor demand and the potential for further capital infusion. This financing activity is significant for DexCom as it provides substantial liquidity. Convertible senior notes offer a unique financing structure, allowing the company to raise funds while providing investors with the potential for equity upside if DexCom's stock price increases. The relatively low coupon rate of 0.375% indicates favorable borrowing costs for DexCom, reflecting confidence in its financial health and future prospects.
DEXCOM INC 8-K Report, Corporate Update (May 2, 2023)
DexCom, Inc. (DXCM) announced on May 2, 2023, its intention to offer $1.0 billion in aggregate principal amount of Convertible Senior Notes due 2028 through a private placement to qualified institutional buyers. The company also has the option to issue an additional $150.0 million in notes to cover overallotments. This offering, subject to market conditions, signals DexCom's strategy to potentially raise significant capital to fuel its growth initiatives or manage its financial structure. Investors should note that this is a proposed offering and the final terms, including interest rates and conversion features, are not yet disclosed in this 8-K filing. However, the substantial amount indicates a significant financial maneuver. The use of convertible senior notes suggests a strategy that could balance debt financing with potential equity dilution, depending on the conversion performance over time. Further details will likely be available in subsequent filings as the offering progresses.
DEXCOM INC 8-K Report, Financial Results (Apr 27, 2023)
DexCom, Inc. (DXCM) announced its first-quarter 2023 financial results on April 27, 2023, via a press release. While the filing itself is brief, primarily referencing the press release for detailed operational and financial information, it signifies the company's proactive communication of its performance. Investors should refer to the furnished press release (Exhibit 99.1) for comprehensive details on revenue, profitability, and any forward-looking statements or guidance provided by the company for the period ending March 31, 2023. The information provided in this 8-K filing is furnished and not deemed "filed" under Section 18 of the Exchange Act, meaning it does not carry the same level of liability. However, it is a crucial update for understanding DexCom's recent financial standing and operational progress in the diabetes technology market. Investors and analysts are encouraged to review the full press release to gain a complete picture of the company's performance and outlook.
DEXCOM INC 8-K Report, Financial Results (Feb 9, 2023)
DexCom, Inc. (DXCM) filed an 8-K on February 9, 2023, to report its financial results for the fourth quarter and full year ended December 31, 2022. The filing primarily consists of a press release detailing these results and related information. While the 8-K itself does not contain the detailed financial tables, it serves as the official notification of the company's performance, directing investors to the furnished press release for specifics. Investors should review the press release (Exhibit 99.1) for comprehensive data on revenue, profitability, and any forward-looking statements made by the company. This report is crucial for understanding DexCom's recent operational and financial standing. The information furnished is not considered "filed" for regulatory purposes under Section 18 of the Exchange Act, but it is the primary source for the company's stated performance metrics and outlook as of the filing date. Investors are advised to consult the actual press release for a complete picture of the company's financial condition and results of operations.
DEXCOM INC 8-K Report, Financial Results (Jan 9, 2023)
DexCom, Inc. (DXCM) has provided preliminary, unaudited financial results for the fourth quarter and full fiscal year 2022, along with an initial outlook for fiscal year 2023, during an investor conference. For Q4 2022, the company expects revenue to reach at least $815 million, marking a 17% increase year-over-year. Full-year 2022 revenue is projected to be approximately $2.91 billion, up over 19% from 2021, demonstrating strong top-line growth. Looking ahead to fiscal year 2023, DexCom anticipates total revenue to be in the range of $3.35 billion to $3.49 billion. These preliminary results are subject to finalization as part of the upcoming Form 10-K filing. Investors should note that these are forward-looking statements and actual results may differ due to various risks and uncertainties detailed in DexCom's SEC filings.
DEXCOM INC 8-K Report, Financial Results (Oct 27, 2022)
DexCom, Inc. (DXCM) filed an 8-K on October 27, 2022, to report its financial results for the third quarter ended September 30, 2022. The primary purpose of this filing is to provide investors with updated financial performance information through an accompanying press release, furnished as Exhibit 99.1. While the 8-K itself does not contain detailed financial tables or commentary, it directs investors to the press release for the specific operational and financial condition details of the quarter. Investors should refer to Exhibit 99.1 for key metrics such as revenue, profitability, and any forward-looking statements or guidance provided by the company for the period.
DEXCOM INC 8-K Report, Executive Changes (Aug 31, 2022)
DexCom, Inc. (DXCM) announced a significant internal promotion via an 8-K filing on August 31, 2022, detailing an event on August 25, 2022. Jacob S. Leach has been appointed as the new Executive Vice President, Chief Operating Officer. Mr. Leach is a long-tenured executive within DexCom, having previously served as Executive Vice President, Chief Technology Officer since 2018, and holding various research and development roles since 2004. This promotion reflects a strategic move to leverage his extensive experience within the company, particularly his deep background in glucose sensing systems development, into a broader operational leadership role. In connection with his new position, Mr. Leach's annual base salary has been increased to $600,300. He will also be eligible for an annual cash performance bonus, with a target set at 75% of his base salary. The determination of the actual bonus amount will be at the discretion of the Board's compensation committee. This appointment and compensation adjustment indicate a commitment to internal talent development and a structured approach to executive leadership within DexCom.
DEXCOM INC 8-K Report, Corporate Update (Aug 5, 2022)
DexCom, Inc. announced on August 1, 2022, that it has entered into an accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank, N.A. for up to $700.0 million of its common stock. The company has already made an initial payment of $700.0 million and received an initial delivery of approximately 3.0 million shares on August 3, 2022. This ASR is part of the company's previously authorized $700.0 million share repurchase program, which has a completion deadline of June 30, 2023.
DEXCOM INC 8-K Report, Financial Results (Jul 28, 2022)
DexCom, Inc. (DXCM) filed an 8-K on July 28, 2022, to announce its financial results for the second quarter ended June 30, 2022. The report primarily references a press release containing these results, which is furnished as an exhibit. While this filing itself is not deemed "filed" for certain regulatory purposes, the information within the press release provides key operational and financial updates for investors. Investors should refer to the accompanying press release for detailed financial performance metrics and forward-looking statements. This 8-K serves as a notification of the company's Q2 2022 performance as detailed in their earnings release. The filing does not contain extensive new disclosures beyond what was presented in the press release but is crucial for confirming the timing and public dissemination of the company's quarterly financial information. Investors are encouraged to review the furnished press release for a comprehensive understanding of DexCom's financial condition and results of operations for the period.
DEXCOM INC 8-K Report, Corporate Update (Jul 28, 2022)
DexCom, Inc. (DXCM) announced on July 28, 2022, that its Board of Directors has authorized a significant share repurchase program. The company intends to buy back up to $700 million of its outstanding common stock. This program is set to conclude no later than June 30, 2023, providing a clear timeframe for the buyback activity. The authorization signals management's confidence in the company's value and its commitment to returning capital to shareholders.
DEXCOM INC 8-K Report, Executive Changes (Jul 8, 2022)
DexCom, Inc. (DXCM) has announced the resignation of Chad M. Patterson, Executive Vice President of Global Marketing. Mr. Patterson's resignation will be effective on July 15, 2022. The reason cited for his departure is to pursue another employment opportunity. While the departure of a key executive like the EVP of Global Marketing can sometimes raise questions, the filing indicates that this is a voluntary resignation to accept a position elsewhere. Investors should monitor future communications for any immediate impact on marketing strategies or leadership transitions within the global marketing division.